UiPath (NYSE:PATH) has launched agentic AI automation tools tailored for healthcare providers and payers. The company is partnering with Genzeon to target data management and revenue cycle workflows.

UiPath’s blended fair value estimate has been trimmed from US$16.19 to US$15.93, a move that sits alongside bullish analyst price targets up to US$18 and recent target cuts from more cautious voices.

UiPath, Inc. (NYSE:PATH) is one of the cheap AI stocks to buy in 2026. On February 23, 2026, UiPath announced a suite of agentic AI solutions for healthcare providers and payers, targeting ...

By 2025, AI had become the dominant destination for venture capital again, not because total VC was booming, but because ...

UiPath (NYSE:PATH) has launched agentic AI automation solutions focused on healthcare, targeting workflows such as medical ...

A six-state pilot program will target 'wasteful care' under Medicare Medicare programs in six states will face prior authorizations under a new pilot program. Traditional Medicare in six states will ...

CMS said Cohere Health, Genzeon Corp., Humata Health, Innovaccer, Virtix Health and Zyter will participate as vendors in the pilot. In November, six House Democrats introduced legislation to shut down ...

The information above is compiled from the publicly available data on the MCA website. To confirm any details or get the latest status, please consult the official Ministry of Corporate Affairs (MCA) ...

Harsh Singh, Genzeon General Manager, healthcare division, discussed the company’s efforts to solve administrative overhead challenges in healthcare to support clinicians. Its health tech seeks to ...

A total of five bids have been submitted for the construction of the long-distance tunnel on railway line no. 85 in Łódź, Poland. The process of evaluating and verifying the bids will now commence, ...